Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study

Transplantation
H EsperouI Durand-Zaleski

Abstract

Allogeneic hematopoietic stem-cell transplantation is a widely used, cost-intensive procedure. Our purpose was to estimate costs and determine cost predictors. We used data from a prospective French study comparing four doses of immunoglobulins. Resource use of hematopoietic stem-cell transplant recipients during the first 6 months posttransplant, both inpatient and ambulatory costs, in 85 patients from five centers were collected prospectively and costed. Baseline data and clinical events were retrieved. Protocol-driven costs were excluded. Multivariable analysis evaluated the association between costs and patient's pretransplant status and transplant-related complications. Because of the absence of differences in outcome among the four randomization groups, cost data for all patients were pooled. Total costs per patient were the following: mean 76,237 Euros; standard deviation 32,565 Euros; median 69,516 Euros; range 183,758 to 14,761Euros. The major cost driver was hospital days. No association was found between costs and baseline status. The "predictors" of higher costs (adding an average 20,000 Euros/patient) were the occurrence of transplant-related complications: graft-versus-host disease and repeated infections that wer...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Mar 24, 1994·The New England Journal of Medicine·J O Armitage
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J LeeJ H Antin
Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber

❮ Previous
Next ❯

Citations

May 19, 2010·Bone Marrow Transplantation·D D PoutsiakaD R Snydman
Oct 22, 2013·Haematologica·Myriam LabopinUNKNOWN Eurocord and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Jul 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karen K BallenNavneet S Majhail
Aug 21, 2009·Pediatric Blood & Cancer·Navneet S MajhailDaniel J Weisdorf
Apr 10, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jaime M PreusslerNavneet S Majhail
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailDaniel J Weisdorf
Apr 10, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Susanne Matthes-MartinGeorg Mann
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Akiko M SaitoStephanie J Lee
Oct 11, 2012·Einstein·Fábio Rodrigues KerbauyNelson Hamerschlak
Jun 16, 2012·Blood·Nandita KheraStephanie J Lee
Sep 7, 2019·Current Medical Research and Opinion·Jonathan SchelfhoutAmit D Raval
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Pia RaananiOfer Shpilberg
Dec 5, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Frida SchainJonas Mattsson
Jun 29, 2021·PharmacoEconomics Open·T Alexander Russell-SmithChristopher Knight

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.